Andrew Joseph

London

Reporter at STAT

Reporter at @statnews, covering health and medicine out of Europe. Past: SA Express-News, SF Chronicle. [email protected]

Featured in: Favicon

statnews.com Favicon

businessinsider.com Favicon

foxnews.com Favicon

huffpost.com Favicon

scribd.com Favicon

cnbc.com

pbs.org

boston.com Favicon

mdpi.com

news.com.au + 110 more

Articles

Sanofi to buy Blueprint Medicines in deal worth more than $9 billion

5 days ago | bostonglobe.com | Andrew Joseph

This story is republished from STAT, the health and medicine news site that’s a partner to the Globe. Sign up for STAT’s free Morning Rounds newsletter here. LONDON — Sanofi said Monday it plans to buy Blueprint Medicines in a deal worth more than $9 billion, as the French pharma firm expands its immunology pipeline, a key focus for the company.
Sanofi to buy Blueprint Medicines in deal worth more than $9 billion

5 days ago | statnews.com | Andrew Joseph

LONDON — Sanofi said Monday it plans to buy Blueprint Medicines in a deal worth more than $9 billion, as the French pharma firm expands its immunology pipeline, a key focus for the company. Sanofi is paying $129 per share in cash for Blueprint, amounting to a $9.1 billion equity value and a 27% premium on the biotech’s closing price on Friday.
Next-gen COPD drug from Sanofi, Regeneron shows mixed results in Phase 3 trials

1 week ago | statnews.com | Andrew Joseph

An experimental COPD medicine from Sanofi and Regeneron Pharmaceuticals produced mixed results in a pair of studies, the companies said Friday, sending both firms’ shares down in early and pre-market trading. The drug, called itepekimab, carries high hopes as the companies look for the next medicine that can produce the successes seen with Dupixent, their jointly marketed blockbuster. Dupixent is approved for a number of immune-mediated diseases, and picked up the green light for COPD last year.
What is WHO without the U.S.? Health officials wrestle with future at annual meeting

2 weeks ago | statnews.com | Andrew Joseph

GENEVA — The U.S. has been accused of acting as an 800-pound gorilla on the global stage. Its absence this week from the World Health Organization’s annual meeting of its members cast it as an equally sized specter. WHO officials and delegates from different countries and aid groups spoke repeatedly of the disruption and crisis in international funding.
With U.S. absent, WHO adopts pandemic treaty aimed at improving vaccine access

2 weeks ago | statnews.com | Andrew Joseph

GENEVA — World Health Organization members on Tuesday adopted a treaty aimed at preparing for and responding to future pandemics, what countries say is both a tangible example of how they’re learning the lessons of Covid-19 and a marker for the continued importance of international collaboration. Health officials hailed the treaty, a goal of which is to enable the more equitable distribution of vaccines and treatments, as a historic milestone.
Lars Fruergaard Jørgensen, CEO of Novo Nordisk, to step down as company seeks a turnaround

3 weeks ago | statnews.com | Andrew Joseph

LONDON — Lars Fruergaard Jørgensen, who led Novo Nordisk as it rode the boom of its obesity and diabetes medications to become one of the biggest players in pharma, only to see that success stall in recent months, is stepping down as CEO, the company said Friday. Jørgensen, who’s worked at Novo for more than 30 years and has been CEO for eight, will continue in the position for a period “to support a smooth transition to new leadership,” the company said. The search for the next CEO is ongoing.
GSK to buy experimental MASH drug for $1.2B upfront

3 weeks ago | statnews.com | Andrew Joseph

LONDON — GSK said Wednesday it would purchase an experimental liver disease medicine from Boston Pharmaceuticals for $1.2 billion upfront, seeking to build up its pipeline of future medicines. The drug, called efimosfermin, is in development to treat a liver condition called MASH, an indication that a number of drugmakers are pursuing. The once-monthly drug is also being considered as a treatment for alcohol-related liver disease.
Trump wants Europe to pay up for drugs to help lower prices for Americans. It won’t be easy

3 weeks ago | statnews.com | Andrew Joseph

LONDON — In announcing his plan to lower prescription drug prices, President Trump argued that both Americans and drug companies could benefit. Critical to making this happen, he said, would be getting Europeans — whom he cast as freeloaders in the global pharmaceutical system — to pay more for their medicines. It may not be so easy.
UnitedHealth names new CEO, suspends 2025 outlook

3 weeks ago | statnews.com | Andrew Joseph

UnitedHealth Group said Tuesday that CEO Andrew Witty had stepped down, citing personal reasons, and that it had named its board chair and former chief executive Stephen Hemsley as the company’s new leader. Hemsley, who was UnitedHealth’s CEO from 2006 to 2017, will remain the company’s chair.
Europe unveils $565 million package to retain scientists, and attract new ones

1 month ago | statnews.com | Andrew Joseph

LONDON — The European Commission on Monday unveiled a roughly $565 million package to retain and attract scientists, as other countries try to leverage the Trump administration’s dismantling of research programs in the U.S. to build up their own enterprises.